Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy (REACH CDM X)
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Tideglusib for the Treatment of Congenital or Childhood Onset DM1 (REACH CDM X)
Sponsor: AMO Pharma Limited
This PHASE2/PHASE3 trial investigates Congenital Myotonic Dystrophy and is currently actively recruiting participants. AMO Pharma Limited leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2023 — Dec 2023 [monthly]
Recruiting PHASE2_PHASE3
Status: Enrolling By Invitation → Recruiting
▶ Show 3 earlier versions
-
Dec 2021 — Jun 2023 [monthly]
Enrolling By Invitation PHASE2_PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Enrolling By Invitation PHASE2_PHASE3
-
Sep 2021 — Nov 2021 [monthly]
Enrolling By Invitation PHASE2_PHASE3
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AMO Pharma Limited
For direct contact, visit the study record on ClinicalTrials.gov .